Skip to content

Sunjeev K Kamboj

Research Department of Clinical, Educational and Health Psychology, University College London, London, UK.

9 papers in the library · 76 citations · publishing 2022-2026

Papers

Development and psychometric validation of a novel scale for measuring 'psychedelic preparedness'.

Scientific reports February 8, 2024 Rosalind G McAlpine, George Blackburne, Sunjeev K Kamboj 24 citations

A new 20-item Psychedelic Preparedness Scale (PPS) was developed and validated to measure how well participants are prepared for psychedelic experiences. Using an iterative Delphi-focus group method and input from clinicians, researchers, and psychedelic users, the scale identifies four factors: Knowledge-Expectations, Intention-Preparation, Psychophysical-Readiness, and Support-Planning. In two large online samples (N = 516 and N = 716) and a psilocybin retreat group (N = 46), the PPS showed excellent reliability and evidence for convergent, divergent, and discriminant validity. People scoring higher on preparedness before a psychedelic experience had better mental health and wellbeing outcomes afterward, indicating the scale can predict who may benefit or be less likely to experience harm.

Pharmacological modelling of dissociation and psychosis: an evaluation of the Clinician Administered Dissociative States Scale and Psychotomimetic States Inventory during nitrous oxide (‘laughing gas’)-induced anomalous states

Psychopharmacology March 26, 2022 Giulia Piazza, G. Iskandar, V. Hennessy et al. 14 citations

Nitrous oxide (N2O) produces dissociative and psychosis-like effects comparable to those of ketamine in healthy volunteers, making it a practical alternative for modeling these experiences outside clinical settings. Analysis of data from three previous studies found that the Clinician Administered Dissociative States Scale (CADSS) and Psychotomimetic States Inventory (PSI) capture largely non-overlapping subjective experiences during N2O inhalation. A three-factor model of dissociation was confirmed, though a two-factor model may be more parsimonious. Psychosis-like symptoms were represented by two negative and two positive symptom factors. The findings suggest both measures should be used together to comprehensively assess anomalous states from dissociative NMDAR antagonists.

Development of a digital intervention for psychedelic preparation (DIPP).

Scientific reports February 19, 2024 Rosalind G McAlpine, Matthew D Sacchet, Otto Simonsson et al. 13 citations

A 21-day self-directed digital course (DIPP) was co-designed to improve psychedelic preparation. The intervention, built on a four-factor model of psychedelic preparedness, was developed through two mixed-methods studies: interviews with 19 past high-dose psilocybin retreat attendees and co-design workshops with 28 current retreat participants. The course includes daily meditation, weekly module exercises, and mood tracking. The authors suggest DIPP offers a scalable, comprehensive tool to enhance safety and therapeutic benefits by addressing knowledge, psychophysical readiness, safety planning, and intention.

Complex slow waves in the human brain under 5-MeO-DMT.

Cell reports July 22, 2025 George Blackburne, Rosalind G McAlpine, Marco Fabus et al. 10 citations

Inhaling a high dose of vaporized synthetic 5-MeO-DMT radically reorganizes low-frequency brain oscillations, making them heterogeneous, viscous, and nonrecurring, and halting their typical forward and backward travel across the cortex. This reorganization also causes broadband neural activity to become more stable and low-dimensional, with increased energy barriers for rapid global shifts. These findings, based on EEG data from 29 healthy individuals, provide a detailed account of how the drug sculpts human brain dynamics and reveal atypical cortical slow-wave behaviors relevant to neuroscientific models of serotonergic psychedelics.

Perceived changes in mental health and social engagement attributed to a single psychedelic experience in autistic adults: results from an online survey.

Psychopharmacology February 1, 2025 Jack Stroud, Charlotte Rice, Aaron Orsini et al. 8 citations

The majority of autistic participants who completed an online survey reported that their most impactful psychedelic experience reduced psychological distress (82%) and social anxiety (78%) and increased social engagement (70%). A substantial minority (20%) reported undesirable effects such as increased anxiety, with some describing the experience as among the most negatively impactful of their lives. The only substantial predictor of reduced distress was increased psychological flexibility. The findings come from a non-experimental design with biased sampling, so caution is warranted.

The Induction of Dissociative States: A Meta-Analysis.

Biological psychiatry global open science July 1, 2025 Benjamin Brake, Lillian Wieder, Natasha Hughes et al. 5 citations

Dissociative states—disruptions in awareness and perception—occur across many psychiatric conditions and can be modeled in the lab. A meta-analysis of 123 studies (6,692 individuals) measured state dissociation using a standardized scale. At baseline, the largest effects were in dissociative and complex subtypes of posttraumatic stress disorder. In controlled experiments, mirror gazing and several drugs, particularly ketamine and cannabis, induced dissociation as high as or higher than that seen in PTSD. Results were highly variable across studies but not explained by methodological differences. These findings validate experimental methods for inducing dissociation and inform monitoring of adverse events in drug-based interventions.

How to set up a psychedelic study: Unique considerations for research involving human participants.

Neuroscience and biobehavioral reviews July 1, 2026 Marcus J Glennon, Catherine I V Bird, Prateek Yadav et al. 2 citations

Setting up a psychedelic research study involves a long, arduous, and Kafkaesque process with many unstandardised challenges. These complexities challenge existing assumptions about psychiatric prescribing, the placebo effect, and definitions of selfhood. This review brings together major UK psychedelic research teams to formalise these unique considerations, addressing sociocultural, political, legal, pharmacological, safety, study design, and experiential facets. It identifies continuing areas of debate and provides a practical, experience-based guide with recommendations for policymakers and future researchers intending to set up a psychedelic study or clinical trial.

Development and validation of a short-form (6-item) version of the clinician-administered dissociative states scale (CADSS-SF).

European journal of psychotraumatology December 1, 2026 V Ursule Taujanskaite, Sunjeev K Kamboj

A 6-item short form of the Clinician Administered Dissociative States Scale (CADSS-SF) was developed using data from three studies of nitrous oxide in 229 healthy volunteers, then validated in 80 separate participants. The single-factor scale, composed of derealization and depersonalization items, showed excellent model fit and internal consistency (omega = 0.87), correlated strongly with the full 19-item CADSS (r ≥ 0.88), and moderately with a measure of psychotomimesis (r = 0.63). The CADSS-SF enables rapid, repeated assessment of dissociation during drug intoxication without disrupting the experience, but primarily captures derealization and depersonalization and requires further validation beyond drug-induced dissociation in healthy populations.

Digital Intervention for Psychedelic Preparation (DIPP): protocol for a randomised controlled feasibility trial comparing meditation- and music-based programmes in healthy volunteers.

BMJ open March 12, 2026 Rosalind McAlpine, Magdalena Jaglinska, Krisztina Jedlovszky et al.

A 21-day mobile-accessible programme called the Digital Intervention for Psychedelic Preparation (DIPP) is being tested for feasibility and preliminary efficacy in a randomised controlled trial. The study will recruit 40 non-treatment-seeking adults without a clinical diagnosis, randomly assigning them to either a guided meditation with music condition or a music-only condition. After the digital intervention, all participants will attend an in-person supervised psilocybin session with a standardised 25 mg dose. Primary outcomes include recruitment efficiency, retention, and adherence; secondary outcomes assess preparedness, quality of the psychedelic experience, and wellbeing, with follow-ups up to 9 months. The trial is registered as NCT06815653.